This paper extends the prognostic value of securin immunohistochemistry in invasive breast cancer on the basis of patient material (n=310) obtained during a mammographic screening programme and followed up for a maximum of 20 years. The gene discussed is PTTG1; the disease is invasive breast carcinoma.